Biomarkers for Alzheimer's disease

Expert Review of Molecular Diagnostics

Volumn 7, Issue 5, 2007, Pages 635-646

  Ward, Malcolm ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid biomarkers; Imaging; Mass spectrometry; PET ligands; Phosphorylation; Tau

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; ALPHA1 GLYCOPROTEIN; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CATHEPSIN D; CD5 ANTIGEN; CLUSTERIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4B; COMPLEMENT FACTOR H; CONTACTIN; CYSTATIN C; DESMOPLAKIN; FIBRIN; HEMOPEXIN; IMMUNOGLOBULIN G; NERVE CELL ADHESION MOLECULE; PLASMINOGEN; PREALBUMIN; RETINOL BINDING PROTEIN; VITAMIN D BINDING PROTEIN; VITRONECTIN; PLASMA PROTEIN;

ALZHEIMER DISEASE; BLOOD SAMPLING; CEREBROSPINAL FLUID; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG MONITORING; DRUG RESPONSE; DRUG TARGETING; GENETIC TRAIT; HUMAN; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEOMICS; REVIEW; BRAIN; EUROPE; GENETIC PREDISPOSITION; GENETICS; PATHOLOGY; PREVALENCE; PROTEIN CEREBROSPINAL FLUID LEVEL; SENILE PLAQUE; UNITED STATES;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BLOOD PROTEINS; BRAIN; CEREBROSPINAL FLUID PROTEINS; EUROPE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PREVALENCE; SENILE PLAQUES; UNITED STATES;

EID: 35148855604     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.7.5.635     Document Type: Review

References (56)

1. Hebert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis. Assoc. Disord. 15, 169-173 (2001).
2. Giannakopoulos P, Herrmann FR, Bussière T et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60, 1495-1500 (2003).
3. Nagy Z, Esiri MM, Jobst KA et al. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia 6, 21-31 (1995).
4. Haroutunian V, Purohit DP, Perl DP et al. Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch. Neurol. 56, 713-718 (1999).
5. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment clinical characterisation and outcome Arch. Neurol. 56, 303-308 (1999).
6. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 39(1), 17-23 (2007).
7. Morishima-Kawashima M, Han X, Tanimura Y et al. Effects of human apolipoprotein E isoforms on the amyloid β-protein concentration and lipid composition in brain low-density membrane domains. J. Neurochem. 101(4), 949-958 (2007).
8. Wilkins MR, Pasquali C, Appel RD et al. From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology 1, 61-65 (1996).
9. Gygi SP, Rist B, Gerber SA et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17, 994-999 (1999).
10. Steen H, Pandey A. Proteomics goes quantitative: measuring protein abundance. Trends Biotechnol. 9, 361-364 (2002).
11. Heck AJ, Krijgsveld J. Mass spectrometry-based quantitative proteomics. Expert Rev. Proteomics 3, 317-326 (2004).
12. Kuhn K, Thompson A, Prinz T et al. Isolation of N-terminal protein sequence tags from cyanogen bromide cleaved proteins as a novel approach to investigate hydrophobic proteins. J. Proteome Res. 6, 598-609 (2003).
13. Thompson A, Schäfer J, Kuhn K et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal. Chem. 75, 1895-1904 (2003). • Demonstrates the use of isobaric tagging approaches for the quantitation of proteins in complex mixtures.
14. Ross PL, Huang YN, Marchese JN et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell Proteomics 12, 1154-1169 (2004). • Further demonstration of the utility of isobaric tags.
15. Choe LH, Dutt MJ, Relkin N, Lee KH. Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease. Electrophoresis 23, 2247-2251 (2002).
16. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res. Mol. Brain Res. 118(1-2), 140-146 (2003). •• First of several papers cited that report the identity of differentially expressed proteins occurring in the cerebrospinal fluid (CSF) of Alzheimer's disease (AD) patients. Being closer to the brain, CSF may contain biomarkers in higher abundance compared with plasma.
17. Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol. Res. 28, 155-163 (2006).
18. Finehout EJ, Franck Z, Lee KH. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis. Markers 21, 93-101 (2005).
19. Davidsson P, Westman-Brinkmalm A, Nilsson CL et al. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 13, 611-615 (2002).
20. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann. Neurol. 61, 120-129 (2007).
21. Zhang R, Barker L, Pinchev D et al. Mining biomarkers in human sera using proteomic tools. Proteomics 4, 244-256 (2004).
22. Carrette O, Demalte I, Scherl A et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3, 1486-1494 (2003).
23. Huang JT, Leweke FM, Oxley D et al. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med. 11, E428 (2006).
24. Selle H, Lamerz J, Bueger K et al. Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer's disease. Comb. Chem. High Throughput Screen. 8, 801-806 (2005).
25. Todaro L, Puricelli L, Gioseffi H et al. Neural cell adhesion molecule in human serum. Increased levels in dementia of the Alzheimer type. Neurobiol. Dis. 15, 387-393 (2004).
26. Hye A, Lynham S, Thambisetty M et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129, 3042-3050 (2006). •• Most proteomics studies have reported protein changes in CSF, but plasma represents an attractive sample fluid because it is easier to access. This robust study shows the potential of plasma as a source of protein biomarkers. It is also important that a well-defined set of plasma samples was chosen. Extensive collections of both CSF and plasma will be required for further biomarker discovery and validation.
27. Zhang J, Goodlett DR, Montine TJ. Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases. J. Alzheimers Dis. 8(4), 377-386 (2005).
28. Abdi F, Quinn JF, Jankovic J et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Azheimers Dis. 9, 293-348 (2006).
29. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics. (4), 573-588 (2006). •• First publication to demonstrate the use of mass spectrometry assays for proteins in plasma. The authors note that high- and medium-abdundance proteins have value as clinical biomarkers and there is, therefore, much scope for MS-based assays, even without antibodies. An elegant study and a sign of things to come.
30. Butterfield DA, Castegna A. Proteomics for the identification of specifically oxidized proteins in brain: technology and application to the study of neurodegenerative disorders. Amino Acids (3-4), 419-425 (2003).
31. Butterfield DA, Castegna A. Proteomic analysis of oxidatively modified proteins in Alzheimer's disease brain: insights into neurodegeneration. Cell. Mol. Biol. 5, 747-751 (2003).
32. Butterfield DA. Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Res. 1000(1-2), 1-7 (2004).
33. Morishima-Kawashima M, Hasegawa M, Takio K et al. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J. Biol. Chem. 270, 823-829 (1995).
34. Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J. Neurochem. 71, 2465-2476 (1998).
35. Dettmer K, Hammock BD. Metabolomics - a new exciting field within the 'omics' sciences. Environ. Health Perspect. 112(7) 396-397 (2004).
36. Bjorkhem I, Heverin M, Leoni V, Meaney S, Diczfalusy U. Oxysterols and Alzheimer's disease. Acta Neurol. Scand. Suppl. 114(Suppl. 185), 43-49 (2006).
37. Hartai Z, Juhasz A, Rimanoczy A et al. Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease. Neurochem. Int. 50(2), 308-313 (2007).
38. Phillis JW, Horrocks LA, Farooqui AA. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res. Rev. 52(2), 201-243 (2006). •• Comprehensive review of the role of these three enzyme systems, the metabolites produced and the association with neurodegenerative diseases. Section 10.5.1 is devoted specifically to AD and so most relevant to the subject of this article.
39. Yao Y, Clark CM, Trojanowski JQ, Lee VM, Pratico D. Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann. Neurol. 58(4), 623-626 (2005).
40. Montine TJ, Neely MD, Quinn JF et al. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic. Biol. Med. 33(5), 620-666 (2002).
41. Montine TJ, Quinn JF, Milatovic D et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann. Neurol. 52(2), 175-179 (2002).
42. Klunk WE, Panchalingam K, Moosy J, McClure RJ, Pettegrew JW. N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer's disease brain: a preliminary proton nuclear magnetic resonance study. Neurology 42, 1578-1585 (1992).
43. Miller BL, Moats RA, Shonk T, Earnst T, Wooley S, Ross BD. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 187, 433-437 (1993).
44. 1H MRS study. Neurology 57, 626-632 (2001).
45. Valenzuela MJ, Sachdev PS, Wen W, Shnier R, Brodaty H, Gillies D. Dual voxel proton magnetic resonance spectroscopy in the healthy elderly: subcortical-frontal axonal N-acetylaspartate levels are correlated with fluid cognitive abilities independent of structural brain changes. Neuroimage 12, 747-756 (2000).
46. Thulborn K, Martin C, Voyvodic J. Functional MR imaging using a visually guided saccade paradigm for comparing activation patterns in patients with probable Alzheimer's disease and in cognitivdy able elderly volunteers. Am. J. Neuroradiol. 21, 524-531 (2000).
47. Kantarci K, Jack CR Jr. Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease. NeuroRx 2, 196-205 (2004).
48. Benveniste H, Einstein G, Kim KR, Hulette C, Johnson A. Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc. Natl Acad. Sci. USA 96, 14079-14084 (1999).
49. Poduslo JF, Wengenack TM, Curran GL et al. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhancing magnetic resonance imaging. Neurobiol. Dis. 11, 315-329 (2002).
50. Bacskai BJ, Frosch MP, Freeman SH et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch. Neurol. 64(3), 431-434 (2007).
51. 11C)SB-13 PET Am. J. Geriatr. Psychiatry 12, 584-595 (2004).
52. Zipursky RB, Meyer JH, Verhoeff NP. PET and SPECT imaging in psychiatric disorders. Can. J. Psychiatr. Nurs. 52(3), 146-157 (2007).
53. 11C-PIB helped to discriminate AD from frontotemporal lobar degeneration.
54. Rowe CC, Ng S, Ackermann U et al. Imaging β-amyloid burden in aging and dementia. Neurology 68(20), 1718-1725 (2007).
55. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging working group. Consensus report on: molecular and biochemical markers of Alzheimer's disease. Neurobiol. Aging 19, 109-116 (2003).
56. Frank RA, Galasko D, Hampel H et al. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol. Aging 24(4), 521-536 (2003).